The proposed sale is small and conducted under a pre-arranged 10b5-1 plan, so it carries no negative signal. Monitor the actual sale on Form 4 for completion, but no trading action is warranted based on this filing alone.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $108.49entry
- T+1 · 3mo ago +3.61%α +3.36% · $112.41
- T+5 · 3mo ago +6.50%α +6.90% · $115.54
- T+20 · 2mo ago −1.34%α −0.28% · $107.04
- T+60 · 13d ago −20.91%α −20.42% · $85.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Simon Read, an officer of Dianthus Therapeutics, filed a Form 144 to sell 5,550 shares of common stock valued at approximately $624,375, with the sale to be executed through a 10b5-1 plan adopted on May 8, 2026. The filing is a routine advance notice of an intended sale under a pre-arranged trading plan and does not indicate a change in the insider's view of the company's prospects. Given the small size of the proposed sale relative to the company's $6.1B market cap, the filing is neutral and low-impact.
Key Facts
- Officer Simon Read filed a Form 144 to sell 5,550 shares of common stock.
- The estimated aggregate market value of the proposed sale is $624,375.
- The sale is to be made pursuant to a 10b5-1 selling plan dated May 8, 2026.
- The proposed sale represents a very small fraction of the company's $6.1B market capitalization.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 5,550 shares valued at $624,375, representing ~0.01% of market cap.
Risk Factors
- Insider selling could be misinterpreted by the market as a negative signal despite the 10b5-1 plan.
- The actual sale may not occur, but the filing indicates the insider at least considered selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974158-26-000096 |
| Document: 0001974158-26-000096-index.html | 0001974158-26-000096 |
| Document: 0001974158-26-000096.txt | 0001974158-26-000096 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers